[Nonalcoholic steatohepatitis (NASH): therapeutic approaches].
Buscher
H-P
HP
Medizinische Klinik II, DRK-Kliniken Berlin-Köpenick. h.buscher@drk-kliniken-koepenick.de
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001706:Biopsy; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy; D003937:Diagnosis, Differential; D018752:Diet, Fat-Restricted; D004731:Endotoxins / Q000097:blood; D005234:Fatty Liver / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D005235:Fatty Liver, Alcoholic / Q000175:diagnosis; D006801:Humans; D007413:Intestinal Mucosa / Q000382:microbiology; D008019:Life Style; D008099:Liver / Q000473:pathology; D011379:Prognosis; D000637:Transaminases / Q000097:blood; D015431:Weight Loss
D000900:Anti-Bacterial Agents; D000975:Antioxidants; D004731:Endotoxins; D000637:Transaminases
Die nichtalkoholische Steatohepatitis (NASH): Therapieansätze.